US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com
Dallas, TX (PRWEB) December 26, 2014 -- The US represents the largest market for CRC across the countries covered in this report. In 2013, GlobalData’s forecast estimates that sales of branded therapies were $2.23 billion. The US is the largest CRC market due to the high incidence of the disease, high drug treatment rate, and higher drug prices compared with the 5EU, Japan, and China. Increased sales of CRC therapies over the forecast period will be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastasis patients, and the launch of expensive new therapies that provide further treatment options for patients in later-line settings, replacing cheaper, generic chemotherapy-only regimens. Complete Report is Available @ http://www.reportsnreports.com/reports/321065-colorectal-cancer-us-drug-forecast-and-market-analysis-to-2023.html .
Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. Cancer of the colon is a dangerous tumor that starts in cells of the colon or anus. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.
Order a Purchase copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=321065 .
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
4.2 US
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles — Major Brands
5.2.1 Avastin (Bevacizumab)
5.2.2 Erbitux (Cetuximab)
5.2.3 Vectibix (Panitumumab)
5.2.4 Stivarga (Regorafenib)
5.2.5 Zaltrap (Ziv-Aflibrcept)
5.2.6 Lonsurf (TAS-102)
5.2.7 Xeloda (Capecitabine)
6 Unmet Need and Opportunity
6.1 Overview
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Cyramza (Ramucirumab)
7.2.2 Imprime PGG
7.2.3 Nintedanib (BIBF-1120)
7.3 Promising Approaches in Early-Stage Development
7.3.1 Anti-Angiopoietin-2 Inhibitors
7.3.2 Strategies for BRAF Mutation-Positive Disease
7.3.3 Strategies for KRAS-Mutation Positive Disease
7.3.4 Immune Checkpoint Inhibitors
8 Market Outlook
8.1 United States
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers – Global Issues
8.1.4 Drivers and Barriers
Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=321065 . (This is a premium report priced at US$4995 for a single user License.)
List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the US Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the US Markets, 2013
Table 6: Country Profile - US
Table 7: Leading Treatments for CRC, 2014
Table 8: Product Profile — Avastin
Table 9: Avastin SWOT Analysis, 2014
Table 10: Product Profile — Erbitux
Table 11: Erbitux SWOT Analysis, 2014
Table 12: Product Profile – Vectibix
Table 13: Vectibix SWOT Analysis, 2014
Table 14: Product Profile – Stivarga
Table 15: Stivarga SWOT Analysis, 2014
Table 16: Product Profile – Zaltrap
Table 17: Zaltrap SWOT Analysis, 2014
Table 18: Product Profile – Lonsurf
Table 19: Lonsurf SWOT Analysis, 2014
Table 20: Product Profile – Xeloda
Table 21: Unmet Need and Opportunity in CRC
Table 22: Product Profile – Cyramza
Table 23: Cyramza SWOT Analysis, 2014
Table 24: Product Profile – Imprime PGG
Table 25: Imprime PGG SWOT Analysis, 2014
Table 26: Product Profile – Nintedanib
Table 27: Nintedanib SWOT Analysis, 2014
Table 28: Anti-Angiopoietin-2 Inhibitors in Development
Table 29: Early-stage Strategies for BRAF Mutation-Positive CRC
Table 30: Early-stage Strategies for KRAS Mutation-Positive CRC
Table 31: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC
Table 32: Sales Forecasts ($m) for Colorectal Cancer in the United States, 2013–2023
Table 33: Key Events Impacting Sales for CRC in the US, 2014
Table 34: CRC Market Drivers and Barriers, 2014
Table 35: US CRC Market Drivers and Barriers, 2014
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, ReportsnReports.com, http://www.reportsnreports.com/, +1 (888) 391-5441, [email protected]
Share this article